NCT06783140View on ClinicalTrials.gov

Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

June 2, 2025

Primary Completion Date

June 2, 2031

Study Completion Date

June 2, 2031

Conditions
Pancreatic Cancer, Advanced or MetastaticBRCA1/2 MutationPALB2 Gene Mutation
Interventions
DRUG

Nab paclitaxel

Paclitaxel Powder For Injectable Suspension Nanoparticle, Albumin-bound Paclitaxel is an albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity.

DRUG

Gemcitabine

Gemcitabine is a hydrochloride salt of an analogue of the antimetabolite nucleoside deoxycytidine with antineoplastic activity.

DRUG

Cisplatin

Cisplatin is an alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity.

Trial Locations (1)

M5G 2M9

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER